pFUSE-mIgG1-Fc2

Plasmid containing a mouse IgG2 Fc region and the IL-2 signal sequence

Catalog code: pfuse-mg1fc2

https://www.invivogen.com/pfuse-migg1-fc

For research use only

Version 20K05-MM

PRODUCT INFORMATION

Contents:

- 20 µg of **pFUSE-mIgG1-Fc2** plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG).

pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells that are commonly used in protein purification systems.

pFUSE-Fc plasmids allow the secretion of Fc-Fusion proteins. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

InvivoGen provides pFUSE-Fc vectors featuring Fc regions from different species and isotypes. Three murine isotypes are available: IgG1, IgG2a and IgG3. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In ADCC, the Fc region of an antibody binds to Fc receptors (FcγRs) on the surface of immune effector cells such as natural killers and macrophages, leading to the phagocytosis or lysis of the targeted cells. In CDC, the antibodies kill the targeted cells by triggering the complement cascade at the cell surface IgG isoforms exert different levels of effector functions increasing in the order of mIgG1<mIgG3<mIgG2a.

WARNING: mIgG1-Fc has a very low affinity to Protein A and Protein G making it difficult to purify.

PLASMID FEATURES

- **mIgG1 Fc (mouse):** The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently.
The Fc region of mouse IgG1 mediates low CDC and no ADCC[1].
- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter[2] and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat[3]. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **IL-2 ss:** The IL2 signal sequence contains 21 amino acids and share common characteristics with signal peptides of other secretory proteins. The intracellular cleavage of the IL2 signal peptide occurs after Ser20 and leads to the secretion of the antigenic protein.
- **MCS:** The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA[4].
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus* The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription[5].

1. Kipps TJ. *et al.*, 1985. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med. 161(1):1-17. **2. Kim DW *et al.*, 1990.** Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23. **3. Takebe Y. *et al.*, 1988.** SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72. **4. Carswell S. & Alwine JC., 1989.** Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58. **5. Yu J. & Russell JE., 2001.** Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in E. coli GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
Zeocin™	ant-zn-1


pFUSE-mIgG1-Fc2(IL2ss)
(4187 bp)
SgfI (11)
PvuI (11)
Psp1406I (205)
PvuII (242)
HindIII (246)
Bsu36I (293)
KasI (536)
SgrAI (553)
EcoRI (626)
EcoRV (634)
NcoI (640)
BglII (648)
NdeI (669)
BbsI (689)
Bsu36I (748)
BbrPI (757)
PvuII (805)
XmaI (850)
SmaI (852)
BsrBI (883)
XcmI (1046)
BbsI (1108)
BstXI (1311)
NheI (1333)
HpaI (1473)
XmnI (1566)
AseI (1570)
AlwNI (1666)
SspI (1812)
SwaI (1827)
DraIII (2008)
EagI (2023)
SgrAI (2240)
XmaI (2266)
SmaI (2268)
BsrBI (2307)
BssHII (2318)
PstI (2476)
AseI (2454)
SacII (2598)
HindIII (2580)
StuI (2682)
BspEI (2738)
Bsp120I (2837)
SpeI (2845)
SnaBI (2975)
NdeI (3079)
SdaI (3261)
PstI (3261)
PacI (3268)
BspLU11I (3274)
AlwNI (3690)
PacI (4008)
SwaI (4016)
NotI (4024)
EagI (4024)
hEF1-HTLV prom
IL2ss
mIgG1-Fc
SV40 pAn
ßGlo pAn
Sh ble
EM2KC
hFerL prom
CMV enh
Ori
100


PvuI (11)
SgfI (11)
1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA
101 GAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC
HindIII (246)
Psp1406I (205)
PvuII (242)
Bsu36I (293)
201 GTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCC
301 GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC
401 GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT
KasI (536)
SgrAI (553)
501 TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTGCA
1 MetTyrArgMetGlnLeuLeuSerCysI
EcoRV (634)
BglII (648)
EcoRI (626)
NcoI (640)
NdeI (669)
BbsI (689)
601 TTGCACTAAGTCTTGCACTTGTCACGAATTCGATATCGGCCATGGTTAGATCTGGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTT
10 IeAlaLeuSerLeuAlaLeuValThrAsnSer 1 GlyCysLysProCysIleCysThrValProGluValSerSerValPh
BbrPI (757)
Bsu36I (748)
701 CATCTTCCCCCCAAAGCCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCCGAGGTCCAG
16 ePheProProLysProLysAspValLeuThrIleThrLeuThrProLysValThrCysValValValAspIleSerLysAspAspProGluValGln
XmaI (850)
PvuII (805)
SmaI (852)
BsrBI (883)
801 TTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAGTCAGTGAACTTCCCA
50 PheSerTrpPheValAspAspValGluValHisThrAlaGlnThrGlnProArgGluGluGlnPheAsnSerThrPheArgSerValSerGluLeuProI
901 TCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGG
83 IeMetHisGlnAspTrpLeuAsnGlyLysGluPheLysCysArgValAsnSerAlaAlaPheProAlaProIleGluLysThrIleSerLysThrLysGl
XcmI (1046)
1001 CAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCT
116 yArgProLysAlaProGlnValTyrThrIleProProProLysGluGlnMetAlaLysAspLysValSerLeuThrCysMetIleThrAspPhePhePro
BbsI (1108)
1101 GAAGACATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGACACAGATGGCTCTTACTTCGTCTACA
150 GluAspIleThrValGluTrpGlnTrpAsnGlyGlnProAlaGluAsnTyrLysAsnThrGlnProIleMetAspThrAspGlySerTyrPheValTyrS
1201 GCAAGCTCAATGTGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCACAACCACCATACTGAGAAGAGCCT
183 erLysLeuAsnValGlnLysSerAsnTrpGluAlaGlyAsnThrPheThrCysSerValLeuHisGluGlyLeuHisAsnHisHisThrGluLysSerLe
BstXI (1311)
NheI (1333)
1301 CTCCCACTCTCCTGGTAAATGATCCCAGTGTCGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAA
216 uSerHisSerProGlyLys•••
HpaI (1473)
1401 AAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG
AseI (1570)
XmnI (1566)
1501 TTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTT
AlwNI (1666)
1601 AACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTC
1701 ACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCT
SspI (1812)
SwaI (1827)
1801 TTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATAT
1901 CCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCT
125 •••AspGlnGluGluA
DraIII (2008)
EagI (2023)
2001 GCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCC
119 laValPheHisValCysAsnGlyAlaProAspArgLeuAlaPheGluArgGlyTrpProGlnGluGlyIleGluThrMetAlaProGlySerAlaAspAr
2101 GGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTG
86 gPheAsnThrSerValValGluSerTrpGluAlaTyrLeuGluAspLeuGlyArgValTrpValTrpAlaLeuThrAsnAspProValValGlnAspGln
XmaI (2266)
SgrAI (2240)
SmaI (2268)
2201 GACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCG
53 ValAlaSerIlePheLeuThrValAspAspArgValValGlyAlaPheAspAspGluValPheAspArgSerPheGlyLeuArgAspThrTrpPheGluV
BsrBI (2307)
BssHII (2318)
2301 ACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttag
19 alAlaGlyAlaValAspArgAlaThrLeuValProValAlaSerThrLeuLysAlaMet
AseI (2454)
PstI (2476)
2401 tacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctg


HindIII (2580)
SacII (2598)
2501 cactgccccatctcctgcccacccttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGG
StuI (2682)
2601 GACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCG
BspEI (2738)
2701 GTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGC
SpeI (2845)
Bsp120I (2837)
2801 GCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCG
SnaBI (2975)
2901 TGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAG
NdeI (3079)
3001 TCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTG
3101 CCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGG
PacI (3268)
PstI (3261)
SdaI (3261)
BspLU11I (3274)
3201 GCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGG
3301 CCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
3401 CCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTT
3501 CTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCC
AlwNI (3690)
3601 CCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAG
3701 GATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTG
3801 CTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTA
3901 CGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGC
EagI (4024)
PacI (4008)
SwaI (4016)
NotI (4024)
4001 TAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTC
4101 TCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA